UK director dealings on 28 May 2026: the snapshot

Across UK-listed companies, the Hargreaves Lansdown / Sharecast director dealings round-up dated Thursday 28 May 2026 highlighted a mix of insider buys and sells. On the buy side, CVS Group's group general counsel Scott Morrison purchased 987 shares at 1,269.68p, for £12,531.75. Naked Wines director Jack Pailing was listed as buying 26,500 shares at 75.00p (£19,875.00) and 26,250 shares at 75.00p (£19,687.50). Pharos Energy chief executive Katherine Roe purchased 5,355 shares at 27.50p, for £1,472.63.

On the sell side, Star Energy chief executive Ross Glover sold 289,541 shares at 16.00p (£46,326.56) and chief financial officer Frances Ward sold 60,475 shares at 16.00p (£9,676.00). Both sales were attributable to option-related tax obligations.

Director dealings explained: the rules and the reasoning

Director dealings are share transactions carried out by company directors or persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. Under the UK Market Abuse Regulation (UK MAR), such transactions must be disclosed to the market within three Business days of the trade. These filings are published via the London Stock Exchange's Regulatory News Service (RNS) and republished by data providers including Sharecast, Hargreaves Lansdown and Investegate.

For private investors, director dealings have long been one of several signals worth tracking. Academic and broker research suggests that aggregated director buying can, over time, modestly outperform broader benchmarks, although results vary widely by company and by year. Director purchases are often interpreted as a sign of management confidence, while director sales can have many explanations, including tax planning, Diversification, the funding of share option exercises, or simple personal Liquidity needs. None of these transactions, on their own, indicates wrongdoing or future performance, but investors may still watch them closely as one input among many.

CVS Group in focus: a small CVSG director buy

Scott Morrison's £12,531.75 share purchase at CVS Group is small in absolute terms but adds to the broader UK insider buying watchlist. The FTSE 250 vet services group has been working through a more challenging share price period amid the ongoing CMA market investigation into the Supply of veterinary services for household pets. A modest director buy may add a small confidence signal, but the more important catalysts for CVSG shares are likely to remain operational and regulatory.

Investors interested in the CVSG Investment case typically focus on UK vet Demand, Australian expansion, clinical labour cost dynamics and the eventual scope of any CMA remedies.

Naked Wines in focus: turnaround signal or noise?

Naked Wines' director-linked purchases at 75.00p — a combined £39,562.50 — drew attention because the AIM-listed online wine retailer continues to be one of the more discussed UK turnaround stories. Bulls argue that director engagement at current price levels suggests insiders see value, while bears note that the company is still in transition. As ever, director buying is one input among many.

Pharos Energy in focus: Dividend story plus CEO buy

Katherine Roe's £1,472.63 share purchase at Pharos Energy is small but visible because of the seniority of the buyer. Pharos is a London-listed Vietnam and Egypt-focused oil and gas company with a stated focus on dividends, disciplined growth and a strong Balance Sheet. The CEO purchase fits a longer-running pattern of insider engagement at the company.

Star Energy in focus: option-related sales

Star Energy's combined £56,002.56 of director sales is the headline director sell of the day. The CEO and CFO together disposed of 350,016 shares at 16.00p. Importantly, the company has stated that the sales were to satisfy tax and national insurance liabilities arising from the exercise of share Options. This is a routine and well-understood reason for director selling at UK-listed companies.

Director selling can happen for many personal or financial reasons, and the dealing may draw attention, but it should be assessed alongside fundamentals.

How to use a director dealings round-up

Private investors often pay attention to director purchases because the people transacting have a near-front-row seat to operational performance. They know the order book, the pipeline, the customer base and the trading environment. A director who chooses to put personal Capital into the same shares they are paid to manage is, at minimum, signalling that they do not expect a near-term collapse in fundamentals.

However, this signal can be noisy. Directors are sometimes required to maintain a minimum shareholding, and some buys are small relative to a director's overall Wealth. A purchase made by a newly appointed director, for example, can be more about complying with internal shareholding guidelines than a directional view on the share price. Investors may watch director purchases, but they are typically most useful when assessed alongside fundamentals, valuation, guidance and any recent trading updates.

A director dealings round-up should not be read as a stand-alone trading signal. Each transaction has its own context. Investors who use such round-ups effectively typically build watchlists and combine the data with fundamentals, trading updates and broker forecasts.

Bull case across the round-up

Across the day's director buys, bulls might highlight that senior insiders at CVS Group, Naked Wines and Pharos Energy chose to commit personal capital. They could argue that the pattern is consistent with management teams that believe in the longer-term strategy of their companies and that view current share prices as offering reasonable entry levels.

Bear case across the round-up

Bears could point out that all of the buys are modest in absolute terms and that Star Energy's significant director sells, even if tax-related, add to supply at a vulnerable share price level. They could also argue that the underlying business cases — from CMA exposure at CVS Group to the WINE turnaround and small-cap energy risks — remain unchanged by these transactions.

Key risks across the names

Each company in the round-up has its own risk profile: regulatory exposure for CVS Group; subscriber and Working Capital risk for Naked Wines; macro and fiscal risk for Tapir Holdings; oil price, host-country and operational risk for Pharos Energy and Star Energy; and the cycle and discount risks for Baillie Gifford Shin Nippon. Investors building positions should consider these individually and at the portfolio level.

Balanced conclusion

The 28 May 2026 UK director dealings round-up showcases a typical day at the intersection of regulation, transparency and investor interpretation. CVS Group, Naked Wines and Pharos Energy each saw insider buys; Star Energy saw significant insider sales linked to option-related tax. Director purchases are often monitored by the market, and director selling can happen for many personal or financial reasons. None of these transactions, on their own, indicates future share price performance.

UK Market Abuse Regulation and PDMR disclosures explained

Under the UK Market Abuse Regulation (UK MAR), persons discharging managerial responsibilities (PDMRs) at issuers admitted to a UK regulated market or multilateral trading Facility must notify both the issuer and the Financial Conduct Authority (FCA) of every transaction conducted on their own account in the shares or Debt instruments of that issuer, or in related financial instruments. Notification must take place within three business days of the transaction. The issuer is, in turn, required to make the information public promptly via a Regulatory Information Service (RIS) such as the London Stock Exchange's RNS service. The same rules apply to persons closely associated with PDMRs, which can include spouses, dependent children, and certain associated legal entities.

The rationale behind UK MAR is to support market integrity. By requiring rapid, public disclosure of insider transactions, the regulation aims to ensure that investors have access to the same information about board-level engagement with their company's shares. There is also a 'closed period' regime, under which PDMRs are typically prohibited from dealing for a 30-day window before the publication of interim or annual financial reports, unless specific exemptions apply. These rules sit alongside broader UK MAR provisions on insider lists, market soundings and the prevention of insider dealing and market manipulation. For investors, the practical takeaway is that director dealings disclosures are not informal updates: they are mandatory, time-bound notifications made under a regulatory framework that takes market abuse seriously.

Director dealings versus other signals UK investors track

Director dealings are best understood as one input within a broader signal set. Other commonly tracked inputs for UK shares include trading updates (which provide direct commentary from management on operational and financial performance), broker consensus forecasts (which aggregate analyst expectations on Revenue, profit and dividends), short interest data (which indicates the scale of bearish positioning), institutional shareholding changes filed via TR-1 notifications, and Macroeconomic Indicators such as consumer confidence, real wages and interest rates.

In this wider context, a single director purchase or sale is unlikely to be the most informative data point for any given investment decision. Trading updates, annual results and broker upgrades or downgrades usually carry more weight, because they reflect operational data and forward-looking estimates. However, director dealings have one specific advantage: they reflect the actions of insiders who are, by definition, in the best position to understand the company's near-term trajectory. That is why investors may watch director purchases and sales alongside other signals, even when they do not, on their own, indicate future share price performance.

What to watch next

For CVS Group investors, the next set of meaningful disclosures will likely include trading updates from the UK and Australian businesses, any communications relating to the Competition and Markets Authority market investigation into UK vet services, and broader peer-group commentary on clinical labour costs. Investors may also watch for further PDMR dealings, particularly any from board members responsible for capital allocation and strategy. CVSG shares should be considered in the context of these inputs rather than any single director transaction.

Five things investors often overlook about director dealings

First, size matters but is not everything. A small absolute purchase by a senior insider can carry more interpretive weight than a much larger trade by a junior PDMR, particularly when it occurs at a fresh share price low or high. Investors who focus solely on cash values can miss this nuance.

Second, the stated reason for a transaction can transform its meaning. A director sale to fund tax on share option exercises is qualitatively different from a discretionary disposal at the same size and price. The issuer's RNS announcement is the authoritative source for the stated reason and should always be consulted directly.

Third, persons closely associated with PDMRs are subject to the same disclosure regime. Dealings by spouses, dependent children and certain associated legal entities are also disclosed. Aggregator headlines sometimes simplify the attribution, so investors who want full clarity should read the underlying RNS.

Fourth, the share price reaction on the day of a disclosure is often noisy. Intraday moves of less than one percent are unlikely to reflect the dealing itself in any meaningful way. Longer-term share price effects, if any, are typically driven by fundamentals.

Fifth, director dealings are one input among many. They are best read alongside trading updates, broker forecasts, balance sheet data, valuation metrics and macroeconomic context. The dealing may draw attention, but it should be assessed alongside fundamentals.